Global Health at the Crossroad of Industry and Science
If rainy season in Southeast Asia comes early—as it has this year and steadily has for the last several—so does the Aedes aegypti mosquito, and the dengue virus it carries. In 2013, severe dengue seized Thailand’s people and strained government resources when the country saw 140,000 dengue cases and 129 deaths, the country’s […]
Kineta Awarded NIH/NIAID Contract to Develop New Therapies for Viral Diseases
BVGH Membership Program member, Kineta, Inc. has been awarded an NIH/NIAID research contract to develop new therapies for viral pathogens such as Ebola, influenza A and B, dengue, West Nile, and Lassa viruses, among others. Kineta’s novel antiviral therapy works by activating the human host’s innate immune response to viruses. Click here to read Kineta’s press release.
BVGH Coordinates Ebola Therapeutic Monoclonal Antibody Project
BVGH is coordinating a collaborative initiative to discover, develop, and deliever fully human, broad spectrum, protective anti-Ebola virus monoclonal antibodies. Theraclone Sciences, Inc., a Seattle-based biotechnology company, will lead the R&D effort and co-manage the project with BVGH. Theraclone will receive up to 4.4 million USD from the Wellcome Trust and other funders for this work. "New collaborative approaches with researchers and clinicians from impacted countries, disease experts, and antibody therapeutic scientists from biotechnology companies are desperately needed to develop new and effective products," said Jennifer Dent, president of BVGH. A press release from Theraclone with further detail is available here. Updated Ebola product pipelines, maintained by BVGH, are available here.
2015 Patents for Humanity Awards for Medicine Given to Sanofi and Novartis
Two WIPO Re:Search members, Sanofi and Novartis, were awarded 2015 Patents for Humanity Awards for their work on expanding development and access of drugs. Novartis provided their entire tuberculosis R&D program to TB Alliance to develop new therapies, especially for drug-resistant forms of the disease. Sanofi, in partnership with PATH, University of Calfornia at Berkeley, and Amyris, Inc., and with funding from the Bill and Melinda Gates Foundation, has developed and is manufacturing synthetic artemisinin anti-malarial compounds. Learn more about Sanofi's development and manufacturing process here. More about the 2015 Patents for Humanity Awards is available here.